U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439796) titled 'A Study of ORN252 in Healthy Participants' on Feb. 10.
Brief Summary: The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers - Male and Female
Intervention:
BIOLOGICAL: ORN252
ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Orna Therapeutics, Inc.
Disclaimer: Curated by HT Syndication....